NCT06855706View on ClinicalTrials.gov

An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study

NARecruitingINTERVENTIONAL
Enrollment

120

Participants

Timeline

Start Date

June 4, 2025

Primary Completion Date

April 30, 2027

Study Completion Date

April 30, 2028

Conditions
Endometrial CarcinomaRecurrent Fallopian Tube CarcinomaRecurrent Ovarian CarcinomaRecurrent Primary Peritoneal CarcinomaStage II Fallopian Tube Cancer AJCC v8Stage II Ovarian Cancer AJCC v8Stage II Primary Peritoneal Cancer AJCC v8Stage III Fallopian Tube Cancer AJCC v8Stage III Ovarian Cancer AJCC v8Stage III Primary Peritoneal Cancer AJCC v8Stage IV Fallopian Tube Cancer AJCC v8Stage IV Ovarian Cancer AJCC v8Stage IV Primary Peritoneal Cancer AJCC v8
Interventions
BEHAVIORAL

Behavioral Intervention

Receive personalized PA goals and positive feedback

OTHER

Best Practice

Receive general PA counseling

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

OTHER

Electronic Health Record Review

Ancillary studies

OTHER

Exercise Intervention

Participate in MVPA

OTHER

Medical Device Usage and Evaluation

Wear a Fitbit Sense 2 and CGM device

OTHER

Questionnaire Administration

Ancillary studies

OTHER

Supportive Care

Receive ongoing support

Trial Locations (1)

14263

RECRUITING

Roswell Park Cancer Institute, Buffalo

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

Roswell Park Cancer Institute

OTHER

NCT06855706 - An Automated Personalized Physical Activity Intervention to Improve Immune Function and Clinical Outcomes in Stage II-IV Ovarian, Primary Peritoneal or Fallopian Tube Cancer and Newly Diagnosed Endometrial Cancer, Life on the Go 3 Study | Biotech Hunter | Biotech Hunter